Driving Toward the Elimination of Cancer — Joel Greshock — VP, Oncology, Data Science & Digital Health, Janssen Pharmaceutical Companies of Johnson & Johnson.
Joel Greshock is VP, Oncology, Data Science & Digital Health, Janssen Research & Development (https://www.janssen.com/oncology/leadership-team). In this position, he is responsible for creating unique and actionable medical insights using large and increasingly available datasets. The focus of this research includes discovering novel therapeutic targets, identifying areas of unmet medical need, and enhancing clinical trial recruitment and execution.
Prior to joining Janssen R&D, Joel served as Vice President of Bioinformatics at Neon Therapeutics, Inc., where he built and managed the Data Sciences organization. At Neon, he was responsible for the design and deployment of personalized cancer therapies now under clinical evaluation.
Prior to joining Neon, Joel served as Head of Oncology Translational Informatics for Novartis, where he was responsible for the correlation of patient outcomes with molecular biomarkers, identification of mechanisms of clinical resistance and computational research for assets approaching or being evaluated in early phases of development.
Before joining Novartis, Joel assumed numerous roles for GlaxoSmithKline Oncology, which included Head of Bioinformatics. Earlier in his career, Joel was a Data Analyst at Abramson Family Cancer Research Institute at the University of Pennsylvania, where he built early generation microarray platforms and developed widely used predictive models for cancer predisposition mutations.
Welcome to Futureunity, where we explore the fascinating world of science, technology, and the universe! From the inner workings of the human body to the outer reaches of space, we delve into the latest and most interesting discoveries that are shaping our world. Whether you’re a science buff or just looking for some mind-blowing facts, we’ve got you covered. Join us as we uncover the mysteries of the world around us and discover new frontiers in the fields of science and technology. Get ready for a journey that’s both educational and entertaining!
Disclaimer Fair Use: 1. The videos have no negative impact on the original works. 2. The videos we make are used for educational purposes. 3. The videos are transformative in nature. 4. We use only the audio component and tiny pieces of video footage, only if it’s necessary. Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research. Fair use is a use permitted by copyright statutes that might otherwise be infringing.
Disclaimer: Our channel is based on facts, rumors & fiction.
In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents in all diseased arteries was found to be as safe and effective at one year of follow-up as staged treatment, according to findings from the first large, randomized trial to address this question that is being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. In staged treatment, the blocked artery that caused the heart attack is treated with a stent immediately and other partially blocked arteries are treated in a second procedure up to six weeks later. This study was simultaneously published online in The Lancet at the time of presentation.
About half of patients who have a heart attack have multi-vessel heart disease—this means that in addition to having one completely blocked coronary artery that caused their heart attack, they have additional narrowed coronary arteries that are at risk of becoming blocked or unstable, leading to another heart attack. Clinicians refer to the blocked artery that causes a heart attack as the “culprit lesion” and to the other at-risk arteries as “non-culprit lesions.”
“The purpose of the international, randomized BIOVASC trial was to compare outcomes for immediate and staged complete revascularization for patients with multi-vessel heart disease who have suffered a heart attack. The goal was not to determine which approach was superior but rather to establish whether immediate complete vascularization was ‘not inferior’ to the staged approach, which needed to be answered first,” said Roberto Diletti, MD, Ph.D., an interventional cardiologist at Erasmus Medical Center in Rotterdam, Netherlands, and lead author of the study.
The firm faced financial collapse during the pandemic but is now serving customers in 15 countries.
U.K.-based OneWeb is one launch away from having enough satellites in orbit to cover the entire expanse of the Earth. Once ready, Elon Musk’s Starlink won’t be the only company offering such as service, the BBC
Both OneWeb and Starlink use constellations of satellites in low Earth orbits (LEO) instead of the conventional geostationary orbits (GEO). The lower altitude of the LEO satellites helps in reducing latency or the delay that data takes to make a round trip over a network.
These successes could be taken to indicate that computation has no limits. To see if that’s the case, it’s important to understand what makes a computer powerful.
There are two aspects to a computer’s power: the number of operations its hardware can execute per second and the efficiency of the algorithms it runs. The hardware speed is limited by the laws of physics. Algorithms—basically sets of instructions —are written by humans and translated into a sequence of operations that computer hardware can execute. Even if a computer’s speed could reach the physical limit, computational hurdles remain due to the limits of algorithms.
Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs, has announced it has received protocol concurrence from the FDA for its companion dog longevity study.
Longevity. Technology: Loyal is on a mission is to help dogs everywhere live longer, healthier lives – and that means taking on the development of the first FDA-approved drugs explicitly intended to extend lifespan and healthspan. On the path to FDA approval, Loyal must run a clinical trial that objectively and robustly demonstrates that its drug extends dogs’ healthy lifespan – and does so safely. However, no-one has developed a dog – or human – longevity drug before, so Loyal is building the path to FDA approval largely from scratch.
Today, Loyal has announced that last week it learned from the FDA that the company has received protocol concurrence for its companion dog longevity study. This is good news for the longevity biotech sector, especially welcome as it comes on the same day that tech lender Silicon Valley Bank collapsed and was put under the control of the US Federal Deposit Insurance Corporation – news that left biotechs and VCs reeling.
The goal of brain imaging is to provide in-vivo measures of the human brain to better understand how the brain is structured, connected and functions. In this talk, we will discuss how to analyze brain imaging data in order to make sense of the large amount of data that comes out of the scanner.
👤 **About the speaker**
[Dr. Camille Maumet](https://twitter.com/cmaumet) is a research scientist in neuroinformatics at Inria, Univ Rennes, CNRS, Inserm in Rennes, France. Her research focuses on the variability of analytical pipelines and its impact on our ability to reuse brain imaging datasets. She obtained her PhD in computer science at the University of Rennes on the analyses of clinical neuroimaging datasets in functional magnetic resonance imaging and. arterial spin labelling. She was then a postdoctoral research fellow in the Institute of Digital Healthcare at the University of Warwick and the University of Oxford. where she focused on meta-analyses and standards for neuroimaging data sharing. She is also an open science advocate. involved in the development of more inclusive research practices and community-led research and participates in many collaborative efforts including Brainhack. the INCF, and the Open Science Special Interest Group of the Organization for Human Brain Mapping that she chaired in 2020. – [Nipype Tutorial](https://miykael.github.io/nipype_tutorial/) – Annual Brain Imaging Events:
The sensor sends out its location as it moves through the GI tract, revealing where slowdowns in digestion may occur.
Engineers at MIT
MIT is an acronym for the Massachusetts Institute of Technology. It is a prestigious private research university in Cambridge, Massachusetts that was founded in 1861. It is organized into five Schools: architecture and planning; engineering; humanities, arts, and social sciences; management; and science. MIT’s impact includes many scientific breakthroughs and technological advances. Their stated goal is to make a better world through education, research, and innovation.
Scientists created mice with two biological dads by producing eggs from male cells, which is a development that opens radical new possibilities for reproduction. Progress can ultimately pave way for treatments for severe infertility forms and increase possibility of attracting couples of same gender to have a biological child in future. Hayashi, who presented development at the third International Human Genome Regulation Summit at Francis Crick Institute in London on Wednesday, predicts it would be technically possible to create a human egg from a male skin cell in ten years. Considering that human eggs did not create eggs, he argued this timeline was optimistic. Previously, scientists have created mice technically with a detailed step chain, including genetic engineering. This is first time that can be applied first time, eggs were raised from male cells and pointing to an important progress. He was trying to reproduce with human cells, but there would be important obstacles for use of eggs grown in laboratory clinical purposes, including creating safety. “In terms of technology, it will be possible even in 10 years in 10 years, ve he personally added that the technology used clinically to allow two men to have a baby. Orum I don’t know if they are ready reproduction,” he said.“This is a question not only for the scientific program, but also[society].” Technique, X chromosome is missing or partially missing a copy of the turner syndrome, including women with severe infertility forms can be applied to treat and Hayashi, this application is the primary motivation for research, he said. Others argued that translating technique into human cells may be challenging. Human cells need much longer agricultural periods to produce a mature egg, which can increase the risk of undesirable genetic changes. Profess George Daley, the Dean of Harvard Medical Faculty, described the study as “fascinating„ but other researches also showed that creating gamet creating from human cells in laboratory is more difficult than mouse cells.said. The study, which was sent to be leading magazine, was based on a number of complex steps to transform skin cell that carries the combination of male XY chromosomes into an egg. Men’s skin cells were re-programmed into a stem cell-like condition to form the induced pluripotent root cells. Then the Y chromosome of these cells was deleted and changed and ” borrowed from another cell to produce IPS cells with two identical X chromosome. Hayashi said, ” The trick, greatest trick, the reproduction of X chromosome,” he said. ” We really tried to establish a system to replicate the X chromosome.” Finally, cells were grown in an ovary organoid with a cultural system designed to replicate the conditions within ovary. When Yumurtas were fertilized with normal sperm, scientists obtained approximately 600 embryos implanted in the mice, which resulted in birth of seven mouse offspring. ‘Efficiency was lower than the efficiency obtained by normal female-derived eggs, where approximately 5% of the embryos continued to produce a lively birth. Baby mice looked healthy, had a normal life, and as an adult continued to the offspring. ” They look good, they grow normal, they become a father, Hay Hayashi said. He and his colleagues are now trying to increase the creation of eggs grown in the laboratory using human cells. Working on Gamets grown in the laboratory at the University of California Los Angeles, Prof Amander Clark said that it would be a ” big jump in, because scientists have not yet created human eggs from women’s cells. Scientists have created the premises of human eggs, but so far, cells, mature eggs and sperm, a critical cell division step, which has stopped development before the point of meiosis. It can be 10 years or 20 years.”
